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Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised
therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster anti-hTNF-α monoclonal
antibodies is well recognised, especially for adalimumab and infliximab treatments, with the large and complex molecular
architecture of classical immunoglobulin antibody drugs, in part, responsible for the immunogenicity seen in patients. The
initial aim of this study was to develop solid-phase enzyme-linked immunosorbent assays (ELISA) and an in vitro cell-based
method to accurately detect ADA and estimate its impact on the preclinical in vivo efficacy outcomes of two novel,
nonimmunoglobulin VNAR fusion anti-hTNF-α biologics (Quad-X™ and D1-NDure™-C4) and Humira®, a brand of
adalimumab. Serum drug levels and the presence of ADA were determined in a transgenic mouse model of polyarthritis
(Tg197) when Quad-X™ and Humira® were dosed at 1mg/kg and D1-NDure™-C4 was dosed at 30mg/kg. The serum levels of
the Quad-X™ and D1-NDure™-C4 modalities were consistently high and comparable across all mice within the same treatment
groups. In 1mg/kg and 3mg/kg Quad-X™- and 30mg/kg D1-NDure™-C4-treated mice, an average trough drug serum
concentration of 8μg/mL, 50 μg/mL, and 350μg/mL, respectively, were estimated. In stark contrast, Humira® trough serum
concentrations in the 1mg/kg treatment group ranged from <0.008μg/mL to 4 μg/mL with trace levels detected in 7 of the 8
animals treated. Trough serum Humira® and Quad-X™ concentrations in 3mg/kg treatment samples were comparable;
however, the functionality of the detected Humira® serum was significantly compromised due to neutralising ADA. The impact
of ADA went beyond the simple and rapid clearance of Humira®, as 7/8 serum samples also showed no detectable capacity to
neutralise hTNF-α-mediated cytotoxicity in a murine fibrosarcoma (L929) cell assay. The neutralisation capacity of all the
VNAR constructs remained unchanged at the end of the experimental period (10 weeks). The data presented in this manuscript
goes some way to explain the exciting outcomes of the previously published preclinical in vivo efficacy data, which showed
complete control of disease at Quad-X™ concentrations of 0.5mg/kg, equivalent to 10x the in vivo potency of Humira®. This
independent corroboration also validates the robustness and reliability of the assay techniques reported in this current
manuscript, and while it comes with the caveat of a mouse study, it does appear to suggest that these particular VNAR
constructs, at least, are of low inherent immunogenicity.
1. Introduction
Therapeutic monoclonal antibodies have seen great success
in the treatment of a wide range of conditions ranging from
autoinflammatory diseases to cancers. Despite these major
therapeutic milestones, a significant risk of immunogenicity
is associated with this class of protein-based therapeutics,
with a real threat of therapeutic failure and even severe
adverse events particularly with anti-TNF-α protein-based
therapeutics [1–7]. A number of drug-related factors have
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been implicated in the initiation of an immunogenic reaction
and include but are not limited to the primary sequence of
the biotherapeutic drug, formulation changes, aggregation,
host-cell specific posttranslational modifications, the pres-
ence of host-cell proteins, chemical modifications (deamina-
tion, oxidation, or glycation), and changes in protein
structure [7–10].
There is overwhelming evidence of an anti-drug antibody
(ADA) being generated in vivo against a number of clinically
important anti-TNF-α biologics, and a direct link between
this ADA response, serum drug disappearance, and
therapeutic failure [1, 3, 10–17]. In one case study, ADA to
Humira® (currently the world’s bestselling drug, 2018) was
detected after three years of treatment in about 28% of 272
Humira®-treated patients, with 67% of those patients
developing ADA after just 28 weeks, resulting in exacerbation
of disease [18].
There is a clear need, especially for these refractory
patients, for a next-generation potent hTNF-α-neutralising
biologic with inherent low immunogenicity. The structur-
ally less complex biologics delivered from the variable
new antigen receptor (VNAR) drug platform, and related
humanised formats known as soloMERs™ [19–22], have
both previously been reported as having inherently low
immunogenicity in a classical dendritic cell-T-cell assay
[21]. Their smaller molecular size, simple single-chain for-
mat, minimal requirements for posttranslational modifica-
tion, and excellent stability, may all contribute to this low
immunogenicity profile.
Immunogenicity assessment has quite rightly become
one of the regulatory cornerstones of biotherapeutic drug
approvals. Unfortunately, the simple prediction of immuno-
genicity and its resulting knock-on clinical significance
remains challenging. However, as methodologies (in silico,
in vitro, and possibly in vivo models) develop, the ability to
more closely predict and mitigate risks of immunogenicity
are beginning to improve, but even with these new
approaches, one single assay of immunogenicity prediction
is probably not achievable. Enzyme-linked immunosorbent
assay (ELISA) is the most commonly used assay platform
for immunogenicity assessment [1, 23]. ELISA assays can
be vulnerable to interference from a range of serum compo-
nents such as rheumatoid factors or excess drug in trough
serum samples, and bridging-type ELISAs (bELISAs) have
been shown to have limited capacity to detect long-lived
IgG4 ADA species [1, 23–27]. Moreover, and like all solid-
phase ELISA techniques, they are sensitive to artefacts such
as epitope shielding and neoepitope formation [1, 12]. How-
ever, if methods are employed to minimise these risks, then
ELISA-based assays are still powerful tools for screening/-
quantifying drug-ADA immune complexes in biological
samples because of their inherent sensitivity, cost/time effec-
tiveness, availability of reagents, assay reproducibility, and
flexibility of assay formats. In contrast to ELISA, cell-based
assays can be designed to give a functional assessment of a
biologically active drug in the presence or absence of ADA
(neutralising and non-neutralising). Regulatory authorities
recommend that cell-based assays, if available and suitable,
are used in concert with other techniques, to quantify neutra-
lising ADA specific for biotherapeutic drugs, and also the
impact of ADA on the functionality of a drug candidate [1, 3].
In this manuscript, we describe the application of
solid-phase ELISA and classical in vitro cell-based
approaches to evaluate the presence of an anti-hTNF-α
drug and ADA in trough mouse serum samples prepared
from a transgenic mouse model of human rheumatoid
arthritis (RA) disease. Analysis compared the level of
ADA production in trough mouse serum samples for
two novel anti-hTNF-α modalities (Quad-X™ and D1-
NDure™-C4) with a clinically available anti-hTNF-α
monoclonal antibody, Humira®. Furthermore, trough
serum drug levels were determined using both direct and
indirect ELISA methods, allowing us to better understand
and correlate the impact of ADA on the preclinical
in vivo efficacy study outcomes of these anti-hTNF-α
drugs [28]. The conventional approach for ADA investiga-
tion is to assess serum samples collected at the end of a
therapeutic cycle (trough level), where the drug level is
low enough to minimise any drug interference in a drug-
sensitive assay but not so low as to limit the clinical use-
fulness of the assay in detecting ADA [1]. Therefore, for
the purpose of this report, we refer to the serum samples
utilised here as “trough” serum samples, only on the basis
that the samples were collected 48 h after the end of a
therapeutic cycle.
2. Materials and Methods
2.1. Protein Drug Formats and Endotoxin Testing. The novel
anti-hTNF-α VNAR Quad-X™ is a 103 kDa engineered
domain with two biparatopic anti-hTNF-α VNAR domains
(VNAR D1 and C4) fused to the hinge region of a wild-
type human IgG1 Fc via a short glycine-rich linker, and
two additional binding domains (VNAR D1 and C4) C-
terminally fused to the CH-3 region of the Fc fragment
via a longer flexible glycine-rich linker creating a quadriva-
lent/biparatopic construct harbouring a wild-type human
IgG1 Fc fragment. A second anti-hTNF-α VNAR drug
D1-NDure™-C4 is a 38 kDa linear bispecific construct of
the two anti-hTNF-α VNAR D1 and C4 domains, respec-
tively, fused via flexible glycine-rich linkers to the N- and
C-terminal regions of a humanised anti-human serum
albumin VNAR, NDure™ [21, 22, 28, 29]. This linear con-
struct incorporates a c-terminal poly-histidine tail and a
protein-L binding site in the framework region of the
HSA binding partner (NDure™) allowing flexibility for
downstream immunodetection and purification. Humira®,
also known as adalimumab, is a commercially available
150 kDa recombinant, fully human IgG1 monoclonal anti-
body specific for hTNF-α [30, 31].
All protein drug samples and sterile D-PBS buffer were
assessed for endotoxin levels by a LAL (Limulus amebocyte
lysate) test using the Pierce™ LAL Chromogenic Endotoxin
Quantitation Kit (Thermo Fisher Scientific, Rockford,
USA). The analysis was performed according to the manu-
facturer’s instructions. All samples were found to have endo-
toxin levels that were within the limit acceptable for the
in vivo study (<1.0 EU/mg).
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2.2. Treated and Untreated Mice Serum Samples. Also
described in a recent original research paper [28], three-
week-old transgenic Tg197 mice were injected subcutane-
ously twice weekly for 7 weeks with anti-hTNF-α Quad-
X™, Humira® at 1mg/kg or 3mg/kg, and D1-NDure™-C4
at 30mg/kg. The vehicle control treatment group received
sterile Dulbecco’s phosphate-buffered saline (D-PBS) twice
weekly for the duration of the treatment. Each treatment
group consisted of 8 sex- and age-matched mice (4♂/4♀).
Following euthanasia 48 h post final drug administration,
blood was drawn from all treated mice via cardiac puncture
and collected into adequately labelled tubes. After 30min
incubation at room temperature to allow clotting, blood sam-
ples were centrifuged for 8min at 3824 x g (6000 rpm) at 4°C.
The supernatants were transferred to clean tubes and further
centrifuged for 8min at 15,294 x g (12,000 rpm) at 4°C. The
resulting trough sera supernatants were collected and stored
at -80°C prior to the commencement of in vitro analysis.
Unless otherwise stated, all data presented in this manuscript
represents trough sera samples collected from all 8 sex-
matched mice per treatment group from a previously
reported in vivo efficacy study [28].
2.3. Direct and Indirect Capture ELISA Detection of Drug and
Drug-ADA Complexes
2.3.1. Detecting Anti-TNF-α Quad-X™ and Humira® in
Treated Mice Sera.MaxiSorp Nunc F96 MicroWell (Thermo
Fisher Scientific, Denmark) clear plates were coated with an
anti-human IgG (Fc specific) antibody produced in goat
(Sigma-Aldrich, USA) using a 1 : 1000 dilution in
phosphate-buffered saline (PBS) pH7.4. Plates were incu-
bated for 1 h at 37°C or overnight (o/n) at 4°C, then washed
three times with PBS/0.1% Tween 20 buffer (PBST) before
adding 4% (w/v) milk-PBS (M-PBS) block solution, and
incubated for 1 h at 37°C. Plates were washed three times
with PBST buffer. As specified previously, PBS-diluted sera
samples were added to designated wells (an additional 2-
fold dilution). Plates were incubated for 1 h at room tem-
perature before washing three times with PBST. A 1 : 1000
dilution in 4% (w/v) M-PBST of anti-human IgG- (Fc spe-
cific) peroxidase antibody produced in goat (Abcam, UK)
was added to the appropriate wells. Plates were further incu-
bated at room temperature for 1 h, before a final wash of 3x
PBST and PBS. Colorimetric signal development was per-
formed using 1-Step™ Ultra TMB-ELISA substrate (Thermo
Fisher Scientific, USA) and neutralised using 1M H2SO4.
Colorimetric intensity was determined using a plate reader
at 450nm. For anti-TNF-α serum drug quantification,
Quad-X™ and Humira® of known concentrations were
included in the assay and detected using anti-human IgG-
(Fc specific) peroxidase antibody.
2.3.2. Detecting Drug-Mouse ADA (mADA) Immune
Complexes in Treated Mice Sera.MaxiSorp Nunc F96 Micro-
Well clear plates were coated with anti-mouse IgG (Fc spe-
cific) antibody produced in goat (Sigma-Aldrich, USA)
diluted 1 : 1000 in PBS. All next steps (washes, blocking,
and serum sample twofold dilutions across designated wells)
were performed as described in Section 2.3.1. A peroxidase-
conjugated anti-human IgG (Fc specific) antibody produced
in goat or a peroxidase-conjugated anti-poly-histidine anti-
body produced in rabbit (Abcam, UK), diluted at 1 : 1000 in
4% (w/v) M-PBST was used for drug-mADA complex
detection. Plates were incubated for 1 h at room tempera-
ture, then washed 3x with PBST and PBS. Colour develop-
ment and acid neutralisation were performed as described
in Section 2.3.1.
Alternatively, MaxiSorp Nunc F96 MicroWell clear
plates were coated with anti-human IgG (Fc specific) anti-
body produced in goat using a 1 : 1000 dilution in PBS. All
next steps were as described in Section 2.3.1. A 1 : 1000
dilution in 4% (w/v) M-PBST of anti-mouse IgG- (whole
molecule) peroxidase antibody produced in sheep (Sigma-
Aldrich, USA) was added to designated wells. Plates were
incubated for 1 h at room temperature, then washed 3x with
PBST and PBS. Colour development and acid neutralisation
were performed as described in Section 2.3.1.
2.3.3. Detecting Drug-mADA Complexes in Treated Mice Sera
Using Direct Capture ELISA.MaxiSorp Nunc F96 MicroWell
clear plates were coated with 1-2μg/mL recombinant hTNF-
α (Invitrogen, USA) or HSA (Sigma-Aldrich, USA), and
plates were incubated for 1 h at 37°C or o/n at 4°C. All next
steps (for D1-NDure™-C4) were as described in Section
2.3.1. A 1 : 1000 dilution of anti-mouse IgG- (whole mole-
cule) peroxidase antibody produced in sheep in 4% (w/v)
M-PBST was added to designated wells. Plates were incu-
bated for 1 h at room temperature and washed 3x with PBST
and PBS. Colour development and acid neutralisation were
performed as described in Section 2.3.1.
2.3.4. Determining Specificity of the Direct Capture ELISA
Using Anti-TNF-α Treated Mice Sera. MaxiSorp Nunc F96
MicroWell clear plates were coated with 10μg/mL human
serum albumin (HSA). All proceeding steps involving wash
steps, blocking, and sera sample twofold dilutions across
designated wells described in Section 2.3.1 were followed. A
detection peroxidase-conjugated anti-human IgG (Fc spe-
cific) antibody produced in goat or an anti-mouse IgG-
(whole molecule) peroxidase antibody produced in sheep
was added to designated wells. As a positive control, an
anti-human serum albumin soloMER, NDure™ (with a
poly-histidine tail) was added at 0.1μg/mL top concentration
and twofold diluted across designated wells. A 1 : 1000 dilu-
tion in 4% (w/v) M-PBST of anti-poly-histidine-peroxidase
antibody produced in rabbit was added to designated wells.
Plates were incubated for 1 h at room temperature and
washed three times with PBST and PBS. Colour development
and acid neutralisation were performed as described in
Section 2.3.1.
2.4. Functional Assessment of Drug in Mice Serum Samples
2.4.1. Direct-Binding ELISA.MaxiSorp Nunc F96 MicroWell
clear plates were coated with 1-2μg/mL recombinant hTNF-
α or HSA. Coated plates were incubated for 1 h at 37°C or o/n
at 4°C. All proceeding steps involving wash steps, blocking,
and sera sample twofold dilutions across designated wells
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described in Section 2.3.1 were followed. A peroxidase-
conjugated anti-human IgG (Fc specific) produced in goat
or an anti-poly-histidine-peroxidase antibody produced in
rabbit was added to designated wells at 1 : 1000 dilution
in 4% (w/v) M-PBST. Plates were incubated for 1 h at
room temperature and washed three times with PBST
and PBS. Colour development and acid neutralisation were
performed as previously described. Functional (nonneutra-
lised) drug in the serum was quantified using known con-
centrations of D1-NDure™-C4, Quad-X™, and Humira® as
standards.
2.4.2. In Vitro L929 Cell-Based Neutralisation Assay. As pre-
viously described [22], a TNF-α-sensitive mouse fibrosar-
coma cell line (L929 cells) was grown to 90% confluence in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Tech-
nologies Ltd., UK) supplemented with 10% (v/v) Gibco®
heat-inactivated fetal bovine serum (Thermo Fisher Scien-
tific, UK) before seeding 5 × 103 cells/well into CELLSTAR®
sterile 96-well cell culture flat-bottom plates, with a lid (Grei-
ner Bio-One, Germany). Seeded cells were incubated for 48 h
at 37°C and 5% (v/v) CO2. Known concentrations of the con-
trol anti-TNF-α D1-NDure™-C4, Quad-X™, and Humira®
and estimated concentrations of drugs in serum samples
were prepared in fresh DMEMmedia before adding to desig-
nated wells containing L929 cells. Cells were immediately
treated with 1μg/mL actinomycin-D and 0.3 ng/mL hTNF-
α and incubated for 24 h before adding a cell proliferation
reagent WST-1 (Roche Diagnostics, Germany). After an
additional 24 h of incubation, cell viability was quantified
by measuring absorbance at 450nm.
2.5. Data Analysis. All experiments reported are the blank
corrected mean of two independent experiments with two
replicates per experiments, unless otherwise stated. Graph-
Pad Prism 8 software was used for graphical presentation
and statistical analyses where necessary. Where required,
p values less than 0.05 were considered as statistically sig-
nificant. Experimental signal cut-off point (threshold) was
determined by analysing ≈64 replicate negative control
(D-PBS-treated serum samples) data using the following
formula: Mean ðnegative controlsÞ + 3 SD ðnegative controlsÞ.
3. Results
3.1. Detection of Serum Anti-TNF-α Drugs (Humira® and
Quad-X™) and Drug-ADA Complex in Pooled Sera
Samples. In a preliminary investigation, using indirect cap-
ture ELISAs, the presence of anti-hTNF-α drugs and drug-
mouse ADA complex was determined in three randomly
selected serum samples per treatment group. For this initial
evaluation, and as this particular technique is unable to dis-
tinguish between functional and nonfunctional proteins,
equal volumes of these selected samples were pooled before
diluting 1 : 20 in sterile PBS and adding to ELISA plates
coated with either anti-human IgG (Fc specific) or anti-
mouse IgG (Fc specific) antibody. The sera Humira® and
Quad-X™ were captured using an anti-human IgG (Fc spe-
cific) antibody and detected with an anti-human IgG- (Fc
specific) peroxidase antibody (Figure 1(a)). Both 1 and
3mg/kg Quad-X™ samples showed consistently high serum
levels of Quad-X™ drug either as free circulating or in com-
plex with mADA. Only the 3mg/kg Humira® sample showed
a comparable serum level of functional or nonfunctional
Humira® drug. Mouse IgG (ADA) to anti-TNF-α drug was
detected in 1mg/kg or 3mg/kg Quad-X™ and Humira®
samples by indirectly capturing the anti-TNF-α drugs with
an anti-human IgG (Fc specific) antibody, and detecting with
anti-mouse IgG- (whole molecule) peroxidase (Figure 1(b)),
but only the 3mg/kg Humira® pooled sample showed the
measurable presence of mouse ADA-bound drug using a
different indirect capture approach (Figure 1(c)). However,
the level of detectable mouse ADA to drug (neutralising
and/or nonneutralising) was consistently higher in all
Humira® serum samples (Figure 1(b)). Anti-TNF-α drugs,
in complex to mouse ADA, were identified by capturing with
anti-mouse IgG (Fc specific) antibody and detecting
Humira® and Quad-X™ in pooled serum using an anti-
human IgG- (Fc specific) peroxidase antibody (Figure 1(c)).
Although only the 3mg/kg Humira® sample showed signifi-
cant levels of drug-ADA complex, this indirect capture
ELISA relies on capturing circulating mouse IgG (drug and
nondrug bound). The detection, therefore, of low or no
drug-mouse ADA complex could mean that either there is
no ADA bound to the drug, or that free circulating serum
mouse IgG preferentially occupied the capture anti-mouse
IgG antibody, especially if levels of circulating drug-mouse
ADA are depleted as a result of drug clearance mediated by
ADA activity. Similarly, in the 10mg/kg Humira®-treated
serum samples, mouse ADA was detected in 4 out of 8 serum
samples of Humira® samples using the approach described in
Figure 1(b), and none was detected using the Figure 1(c)
approach (data not shown). No mouse ADA was detected
in 10mg/kg Quad-X™-treated samples using both methods
(data not shown).
3.2. Detection of Functional Serum Anti-TNF-α Drugs and
Nonneutralising ADA in Pooled Sera Samples. Figures 2(a)
and 2(b) describe a more definitive assessment of anti-
TNF-α drug functionality and nonneutralising ADA,
respectively. In a direct-binding ELISA, serum samples
were added to plates coated with hTNF-α and functional
drug was detected with anti-human IgG- (Fc specific) per-
oxidase antibody (Figure 2(a)), while nonneutralising
mouse ADA was detected with an anti-mouse IgG- (whole
molecule) peroxidase antibody (Figure 2(b)). Except for the
1mg/kg Humira® pooled serum sample, significant levels
of functional drugs were detected in the serum samples
of 1mg/kg and 3mg/kg Quad-X™ and 3mg/kg Humira®
(Figure 2(a)). The presence of potentially nonneutralising
ADA bound to a drug was detected only in the Humira®
3mg/kg pooled samples (Figure 2(b)). This assay reinforces
the rapid functional drug clearance seen with 1mg/kg
Humira® samples and suggests that the 3mg/kg Humira®
may have been cleared more quickly than Quad-X™ samples.
This assumption is based on the minimal levels of nonneutra-
lising mouse ADA in complex with functional drug in both
the 1mg/kg and 3mg/kg serum Quad-X™ samples.
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3.3. Detection of Serum Anti-TNF-α Drugs (Humira® and
Quad-X™) and Drug-ADA Complex in Individual Mouse
Serum Samples. Anti-TNF-α drugs in 1 and 3mg/kg treated
serum samples were detected and quantified using a known
concentration of the drug in PBS buffer as standard, thereby
allowing approximate estimation of the trough amount of
total circulating anti-TNF-α drug in each mouse serum
(Figures 3(a), 3(b), 3(e), and 3(f)). The serum levels of
Quad-X™ in both 1 and 3mg/kg treated samples showed
consistent and significantly higher circulating drug concen-
trations in all treated mice when compared to mice sera from
1 or 3mg/kg Humira® treatments (Figures 3(a), 3(b), 3(e),
and 3(f)). Trough serum drug concentrations in the 1 and
3mg/kg treated Quad-X™ serum samples were on average
8μg/mL and 50μg/mL, respectively, while the trough drug
serum levels in the 1mg/kg Humira®, where a signal was
detectable, ranged from <0.008μg/mL (serum samples 2, 6,
and 7—assay LoD) up to 20μg/mL (serum sample 5), with
an average of 4μg/mL drug in serum samples 1, 3, 4, and 8.
This observation is reinforced by further analysis of serum
samples 2, 6, and 7 (Figure 3(d)) where trace levels of
Humira®-ADA were detected. The levels of drug-mouse
ADA complex in the 1mg/kg Quad-X™ or Humira® sera
were quite variable across individual samples (Figure 3(c)).
For the 3mg/kg Humira®-treated samples, an average trough
serum drug level of 70μg/mL was determined (Figure 3(f)).
While there is again some variation in data sets, the drug-
ADA levels in the 3mg/kg Humira® treatment group
(Figure 3(h)) are higher across some of the serum samples
when compared to 3mg/kg Quad-X™ (Figure 3(g)).
3.4. Detection of Serum Anti-TNF-α D1-NDure™-C4 and
Drug-ADA Complex Levels. Following multiple binding curve

































































Figure 1: Drug and mouse ADA detection using an indirect capture ELISA. (a) Serum anti-hTNF-α Quad-X™ and Humira® were detected
using a capture anti-human IgG antibody (Fc specific) and a detection secondary anti-human IgG antibody- (Fc specific) peroxidase. (b)
Detection of mouse ADA to anti-hTNF-α Quad-X™ and Humira® using a capture anti-human IgG antibody (Fc specific) and detection
with an anti-mouse IgG- (whole molecule) peroxidase. (c) Detection of anti-hTNF-α Quad-X™ and Humira® to drug-specific mouse IgG
using a capture anti-mouse IgG antibody (Fc specific) and a detection antibody, an anti-human IgG antibody- (Fc specific) peroxidase. All
serum samples were randomly pooled and diluted at 1 : 20 in sterile PBS, pH 7.4. The results shown are the mean ± SD (n = 2 with two
replicates per experiment).
5Journal of Immunology Research
factors of 30mg/kg D1-NDure™-C4 serum samples (data not
shown), an initial serum sample dilution factor of 1 : 500 in
sterile PBS produced a typical sigmoidal drug-binding curve.
Circulating serum D1-NDure™-C4 was calculated using a
known concentration of D1-NDure™-C4 recombinant pro-
tein as a control. Using this approach, an average trough
serum level of functional free circulating and/or nonneutra-
lising ADA-complexed D1-NDure™-C4 was calculated to
be 350μg/mL. Functional D1-NDure™-C4 in sera was deter-
mined in an hTNF-α-coated direct-binding ELISA, with
hTNF-α binding detected using an anti-poly-histidine-per-
oxidase antibody (Figure 4(a)). Both the direct (Figure 4(b))
and indirect capture ELISA (data not shown) formats used
here to reveal mouse ADA to D1-NDure™-C4 drug consis-
tently showed no measurable D1-NDure™-C4-specific
ADA in sera. In a previous sensitivity/limit of detection
assay, we established a limit of detection (LoD) for total
mouse IgG in mouse serum samples at ≈1ng/mL. Free circu-
lating mouse IgG in both D1-NDure™-C4- and D-PBS-
treated mice serum samples were detected using an indirect
capture ELISA (Figure 4(c)) demonstrating the robustness
of the assay to detect circulating mouse IgG. This data shows
comparable levels of circulating mouse IgG in both drug- and
D-PBS-treated samples, therefore supporting the observa-
tions that the titre of serum D1-NDure™-C4-specific mouse
ADA is either present at trace levels (below <1ng/mL) or that
the drug did not elicit any mouse ADA. While unlikely, one
alternative interpretation of the data is that drug interference
is due to the high in vivo dosing regimen of D1-NDure™-C4
(30mg/kg). As mentioned earlier, we succeeded in detecting
mouse ADA in complex with Humira® in 10mg/kg treated
serum samples with an initial serum sample dilution of
1 : 100, although drug interference may have limited the
capacity of the assay to detect ADA in all serum samples
(data not shown).
3.5. Assessing In Vitro Functionality of Anti-TNF-α Drug in
Serum Samples. The capacity of circulating serum anti-
hTNF-α drugs to block exogenous hTNF-α-mediated cyto-
toxicity in a sensitised fibrosarcoma cell line (L929) was
assessed in vitro. Both 1mg/kg and 3mg/kg Quad-X™ serum
samples showed no apparent loss of activity with comparable
hTNF-α-neutralising potency to “standard” Quad-X™
recombinant protein (Figures 5(a) and 5(b)). Serum samples
from the second VNAR format, D1-NDure™-C4 serum also
demonstrated comparable potency to control protein in the
L929 cell assay (Figure 5(e)). For the 1mg/kg Humira®-
treated mice serum samples, only one serum sample [5]
showed any (and weak) hTNF-α-neutralising activity
(Figure 5(c)). Although the 3mg/kg Humira® samples
retained more activity compared to the 1mg/kg treatment
group, only traces of activity were recoverable from samples
4 and 5 and only samples 2 and 3 had a potency equivalent
to that of the standard clinical control drug (Figure 5(d)).
All cells treated with D-PBS-treated serum controls, without
the addition of exogenous hTNF-α, showed cell viabilities
comparable to the untreated control cells (Figures 5(a)–
5(d)). This absence of cytotoxicity in the D-PBS-treated
serum samples is because the trough serum level of
endogenously overexpressed hTNF-α in this transgenic
disease model (Tg197) is estimated to be significantly
below the LD50 level (0.25 ng/mL) required for an induc-
tion of cytotoxicity in the sensitised L929 cells. It is
known that circulating hTNF-α levels in Tg197 without
treatment, peaks at week 3 (0.45 ng/mL), followed by a
consistent decline to 0.22 ng/mL at week 6, and a further
steady drop-off in concentration until week 16 [32].
Therefore, this additional experimental control confirms
the absence of experimental artefacts or interference from














































Figure 2: Direct and indirect-binding ELISA for detecting functional serum anti-TNF-α drugs and nonneutralising mouse ADA. (a) Direct-
binding ELISA of serum samples to 2 μg/mL hTNF-α coated wells, with functional drug binding determined using an anti-human IgG
antibody- (Fc specific) peroxidase. (b) Indirect-binding ELISA capturing nonneutralising mouse ADA to anti-hTNF-α drugs. ELISA wells
are coated with 2μg/mL hTNF-α, and nonneutralising mouse ADA was detected using an anti-mouse IgG antibody- (whole molecule)
peroxidase. All serum samples were randomly pooled and diluted at 1 : 20 in sterile PBS, pH 7.4. The results shown are the mean ± SD
(n = 2 with two replicates per experiment).
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3.6. Detection of Nonspecific Binding Signals in Quad-X™ and
Humira® Serum Samples. A final confirmatory assay was
performed to eliminate any possibility of nonspecific binding
signals being detected with either the anti-mouse IgG-
(whole molecule) peroxidase or anti-human IgG- (Fc spe-
cific) peroxidase antibody. Using a direct-binding ELISA
and HSA as an unrelated coating antigen (Figures 6(a) and
6(b)), neither the 1mg/kg Quad-X™, 1mg/kg Humira® nor
D-PBS serum samples (or other unspecified components in
the serum samples) showed any interference with or nonspe-
cific binding to the coated HSA. A similar background inter-
ference assessment was conducted for 3mg/kg Quad-X™ and
Humira® serum samples with a measured absorbance identi-
cal to that of blank controls (data not shown).
4. Discussion
The link between ADA, decreased serum drug concentra-
tion, and clinical efficacy of genetically engineered
immunoglobulin-based anti-hTNF-α biopharmaceuticals
is very well established [3, 13–17]. A number of studies have
followed the immunogenicity of anti-hTNF-α monoclonal
antibodies in patients and reported a strong effect on treat-
ment response in several conditions including RA, inflam-
matory bowel disease, psoriatic arthritis, and psoriasis. In
each case, the presence of ADA was associated with low to
absent serum drug levels, a weakened therapeutic response,
and even an exacerbation of the underlying disease [6, 18,
33–37]. The immunogenicity of Humira® has been described
throughout the drug’s historic approval process, with initial
reports of mouse anti-Humira® antibody (MAHA) and later
primate anti-Humira® antibody (PAHA). Neutralising ADA
was measurable even after a single dose and was reported to
adversely affect drug elimination and potency [38].
We have previously reported superior in vitro and in vivo
efficacy of the anti-TNF-αQuad-X™ over Humira® and have
shown that much of this 10x improvement in potency is due
to the empirical design of the Quad-X™ format [22, 28]. The
low inherent immunogenicity of the VNAR domains and
its humanised soloMER™ derivatives has been previously
confirmed experimentally [21]. Here, the serum levels of
Humira® in treated mice were lower compared with the
Quad-X™-treated samples, with the 1mg/kg Humira®
group showing a severe depletion in drug levels in the
pooled serum samples (Figure 1(a) and 2(a)). In addition,
the functional anti-hTNF-α drug is absent in the 1mg/kg
Humira®-treated samples with this data further supporting
the reported outcome of a preclinical in vivo efficacy study
where 1mg/kg Humira® treatment was ineffective at block-
ing disease progression in Tg197 mice, but complete control
was achieved by Quad-X™ at 0.5mg/kg [28]. Assessing drug
levels in unmasked individual serum samples further rein-
forced the evidence of anti-Humira® mouse ADA-mediated
rapid clearance of Humira® from the systemic circulation
of the treated mice (Figures 3(a)–3(f)). Even the higher levels





















































Figure 3: Indirect capture ELISA determination of anti-hTNF-α drugs and drug-mouse ADA complexes in individual mouse serum samples.
(a and e) Detecting and quantifying serum Quad-X™ in 1mg/kg and 3mg/kg treated mice serum samples diluted at 1 : 40 and 1 : 100 in sterile
PBS, pH 7.4, respectively, prior to adding to designated ELISA wells. Standard anti-hTNF-α Quad-X™ (Quad-X™ Std) was used at a top
known concentration of 0.1 μg/mL. (b and f) Detecting and quantifying serum Humira® in 1mg/kg and 3mg/kg treated mice serum
samples diluted at 1 : 20 and 1 : 100 in sterile PBS, pH 7.4, respectively, prior to adding to designated ELISA wells. Standard Humira®
(Humira® Std) was used at a top known concentration of 1 μg/mL. ELISA wells were coated with an anti-human IgG antibody (Fc
specific), and detection was performed with an anti-human IgG antibody- (Fc specific) peroxidase. (c and g) Indirect ELISA detection of
anti-Quad-X™ mouse ADA to Quad-X™ in 1mg/kg and 3mg/kg Quad-X™-treated serum samples diluted at 1 : 20 and 1 : 50 in sterile
PBS, pH 7.4, respectively, prior to adding to designated ELISA wells. (d and h) Indirect ELISA detection of a mouse ADA complex to
serum Humira® in 1mg/kg and 3mg/kg Humira®-treated serum samples diluted at 1 : 20 and 1 : 50 in sterile PBS, pH 7.4, respectively,
prior to adding to designated ELISA wells. ELISA wells were coated with an anti-human IgG (Fc specific) antibody, while detection of a
drug-ADA complex was performed using an anti-mouse IgG antibody- (whole molecule) peroxidase. The results shown are the mean ±
SD (n = 2 with two replicates per experiment).
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(Figure 3(f)) was only 10% of the corresponding Quad-X™
levels (Figure 3(e)) and would support the partial disease
control seen in vivo with the 3mg/kg Humira® dose
[28]. The levels of mouse ADA in complex with drugs
seen in 1mg/kg Quad-X™-treated samples were compara-
ble to that seen in 1mg/kg Humira® samples
(Figures 3(c) and 3(d), respectively); however, that level
was significantly lower in 3mg/kg Quad-X™ compared to
the corresponding Humira®-treated samples (Figures 3(g)
and 3(h), respectively).
One plausible explanation for the no drug-ADA complex
detection in some samples in Figure 1(c) could be the effect of
steric hindrance caused by excessive mouse ADA bound to
the Fc portion of the drug, thereby blocking the binding of
the anti-human IgG- (Fc specific) peroxidase antibody used

























































































Figure 4: Detection and quantification of serum D1-NDure™-C4 and drug-specific mouse ADA using direct-binding ELISA. (a) Detecting
and quantifying serum D1-NDure™-C4 in 30mg/kg D1-NDure™-C4-treated mice serum samples diluted at 1 : 500 in sterile PBS, pH 7.4
prior to adding to designated ELISA wells. Serum D1-NDure™-C4 was detected and quantified in a direct-binding ELISA with wells
coated with 2μg/mL hTNF-α, and secondary antibody detection was performed using an anti-poly-histidine-peroxidase antibody.
Standard D1-NDure™-C4 (D1-NDure™-C4 Std) was used at a top known concentration of 1 μg/mL. (b) Direct-binding ELISA detection
of mouse ADA to anti-hTNF-α drug in 30mg/kg D1-NDure™-C4 serum samples diluted at 1 : 100 in sterile PBS, pH 7.4 prior to adding
to designated ELISA wells. Detection of drug-specific mouse ADA was determined using wells coated with 2μg/mL hTNF-α and an anti-
mouse IgG antibody- (whole molecule) peroxidase as detection reagent. D1-NDure™-C4 Std (con 1) and D1-NDure™-C4 Std (con 2) are
controls used at known concentrations, with secondary antibody detection using an anti-mouse IgG antibody- (whole molecule)
peroxidase or an anti-poly-histidine-peroxidase antibody, respectively. The results shown are the mean ± SD (n = 2 with two replicates per
experiment). (c) Detection of circulating serum mouse IgG in 30mg/kg D1-NDure™-C4-treated mice serum samples diluted at 1 : 500 in
sterile PBS, pH 7.4 prior to adding to designated ELISA wells. Indirect capture ELISA wells coated with an anti-mouse IgG (Fc specific)
antibody and serum mouse IgG detected using an anti-mouse IgG antibody- (whole molecule) peroxidase were used. The result shown are
the mean ± SD (n = 1 with two replicates per experiment).
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Since the capture antibody is not selective for the mouse IgG
in complex with drug, it is also conceivable that competition
for binding to the capture antibody will persist between free
circulating mouse IgG and the drug-mouse IgG complex.
This competition will favour free circulating mouse IgG if
the level of drug-mouse ADA complex is low, due to drug
clearance for instance, or to the inherent low immunogenic-
ity of the drug (e.g., Quad-X™ samples). For Humira® sam-
ples, it seems more appropriate (when considering the
other assay outcomes) to assume that the negligible levels
of mouse ADA bound to drug captured in the 1mg/kg
pooled serum samples (Figure 1(c)) was due to ADA-
mediated rapid drug clearance. However, even if this
assumption is correct, this potentially contradictory data
does reinforce the fact that these indirect capture ELISA
assays present some challenges when seeking the “best” ana-
lytical approach. We believe our thorough interrogation of
samples, using more than one assay design to test the same
proposition (Figures 1(b) and 1(c)), limits the impact of false
positive or negative outcomes.
The immunogenicity of VNARs and humanised VNARs
(soloMER™) as drug candidates has previously been assessed
in a T-cell proliferation assay, and both developed very low
response index (RI) values [21]. Therefore, the soloMER
domain (NDure™) used in this study, which is fully cross-
reactive with both mouse and human serum albumin [19,
35], was expected to extend the serum half-life of the linear
VNAR fusion protein without encouraging a MAHA
response. This expectation was confirmed by analysis as the
level of functional serum drug was consistently high across
all serum samples tested (Figure 4(a)). Furthermore, using
the same direct functional binding ELISA technique, a
drug-mouse ADA complex was undetectable in all serum
samples (Figure 4(b)). The confidence in this is further rein-
forced in Figure 4(c) where a uniformly high level of free cir-
culating mouse IgG was detected in all test samples. The
assay LoD for circulating mouse IgG was approximately
1 ng/mL, while 8–10ng/mL was obtained as the LoD for
serum D1-NDure™-C4, Quad-X™, and Humira® (data not
shown). These figures are similar to other published studies
[34] and reinforce again the sensitivity and reliability of the
assays used. One additional benefit of this high sensitivity is
the accommodation (without loss of signal) of significant
dilution of trough serum samples, thereby limiting potential
assay interferences from serum anti-hTNF-α drugs or other
uncharacterised mouse serum components.
Regulatory authorities recommend, where possible, the
use of cell-based assays to quantify the effect of neutralis-
ing ADA against biotherapeutic drugs [1, 3, 7, 39]. Cell-
based immunogenicity assessment assays are typically con-
sidered to be difficult to standardise, have low sensitivity,
are time consuming to perform, require a cell culture facil-
ity, and are particularly prone to serum matrix interference
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Figure 5: In vitro functional assessment of serum samples of mice treated with anti-hTNF-α drugs. (a–e) Determination of residual
neutralising capacity of serum anti-hTNF-α drugs in a classical in vitro hTNF-α-induced cytotoxicity assay using a sensitised L929 cell
line. (a and b) Shown are 1mg/kg and 3mg/kg Quad-X™-treated serum samples, respectively (Quad-X™-treated sera vs. D-PBS-treated
sera, p < 0:0001). (c and d) Shown are 1mg/kg and 3mg/kg Humira®-treated serum samples, respectively (Humira®-treated sera vs. D-
PBS-treated sera, p = 0:9991 for all 1mg/kg treated sera except sera 5 (p < 0:001) and p > 0:7 for 3mg/kg treated sera 4 and 5). (e) Shown
are 30mg/kg D1-NDure™-C4-treated serum samples (p < 0:0001 for all D1-NDure™-C4-treated sera vs. D-PBS-treated sera). Exogenous
recombinant hTNF-α at 0.3 ng/mL and 1 μg/mL actinomycin-D were used in all treatment groups except where otherwise stated. No
exogenous hTNF-α and actinomycin-D were added to untreated cells and D-PBS-treated sera (nil hTNF) control groups. Quad-X™ Std
and Humira® Std represent standard known concentrations of the drugs. The results shown are the mean ± SD (n = 2 with three replicates
per experiment). Results were analysed statistically using a two-way ANOVA with multiple comparison post hoc test (p > 0:05 is
considered not significant).
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more reliable when assessing the functionality of serum
drugs and the effect, if any, of ADA on drug function. Neu-
tralisation of hTNF-α-induced cytotoxicity in sensitised
L929 cells remains one of the gold-standard assays for the
in vitro assessment of potency for all anti-hTNF-α biologics.
The L929 assay is known for its high sensitivity and specific-
ity. The functionality of serum Quad-X™ (Figures 5(a) and
5(b)) and D1-NDure™-C4 (Figure 5(e)) in L929 assays
was consistent and statistically significant across all serum
samples, and equivalent to the recombinant protein con-
trols. The 1 and 3mg/kg Humira® serum samples
(Figures 5(c) and 5(d), respectively) showed a significant
loss of drug function in the majority of serum samples, with
the 1mg/kg Humira® samples showing an almost complete
absence of activity. Both the anti-hTNF-α Quad-X™ and
Humira® retain the Fc portion of the human IgG1 molecule;
therefore, the level of recruitment of anti-allotypic mouse
ADA to this particular region would be expected to be com-
parable. However, the Quad-X™ may be protective through
“top-and-tail” steric hindrance introduced by the quadriva-
lent format which places binding sites at both the N and C
terminus of the Fc region, possibly limiting access for anti-
allotypic ADA binders.
In summary, the cell-based functional assays confirm and
mirror the ELISA-based immunogenicity assays for all treat-
ment groups and together this data supports previous in vivo
efficacy data [26].
The primary objectives of this communication were to
present robust and reproducible assay techniques for asses-
sing the functional state of serum VNAR/soloMER™-based
biotherapeutic drugs, and the presence and impact of anti-
drug antibodies in (nonclinical) serum samples. Animal
models, particularly transgenic [37–40], are increasingly
being used to study the immunogenicity of therapeutic pro-
teins, with data generated considered as a predictive guide
to different aspects of immunogenicity assessment during
later drug development. Here, both anti-hTNF-α Quad-X™
and D1-NDure™-C4 consistently showed no impact on func-
tionality in the presence or absence of nonneutralising mouse
ADA. The previously reported and superior preclinical effi-
cacy and now the apparent low immunogenicity of drug
leads support the continued clinical development of the
anti-TNF-αQuad-X™ and D1-NDure™-C4, with in vivo pre-
clinical pharmacokinetic, toxicology, and soloMERisation
(humanisation) of both formats planned as the final develop-
ment steps to clinical candidates. This low inherent immuno-
genicity is in stark contrast to Humira® which has been
dogged by ADA issues throughout its path to clinical
approval and subsequent clinical use, with approximately
one in three patients becoming refractory to extended ther-
apy [16, 40–42].
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Figure 6: Detection of nonspecific background signals in drug- and D-PBS-treated serum samples. (a–b) Detection of a nonspecific binding
response from 1mg/kg Quad-X™- and Humira®-treated mouse serum samples, respectively. In a direct-binding ELISA, 2 μg/mL human
serum albumin (HSA) was used as coating antigen and nonspecific binding was measured using an anti-mouse IgG- (whole molecule)
peroxidase antibody. The results shown are the mean ± SD (n = 2 with three replicates per experiment, except for the pooled NDure™ Std
data which is an n = 4 with two replicates per experiment). p > 0:99 for all Quad-X- and Humira-treated serum samples vs. D-PBS-treated
serum samples, p < 0:0001 for NDure™-treated vs. D-PBS-treated serum samples. Results were analysed statistically using a two-way
ANOVA with multiple comparison post hoc test (p > 0:05 is considered not significant).
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